News Coronavirus EMA starts rolling review of remdesivir for COVID-19

EMA starts rolling review of remdesivir for COVID-19

EMA’s human medicines committee (CHMP) has started a ‘rolling review’ of data on the use of the investigational antiviral medicine remdesivir for the treatment of coronavirus disease (COVID-19).

The start of the rolling review only means that the evaluation of remdesivir has started and does not imply that its benefits outweigh its risks.

A rolling review is one of the regulatory tools available to the Agency to speed up the assessment of a promising investigational medicine during a public health emergency, such as the ongoing pandemic.

Under normal circumstances, all data supporting a marketing authorisation application must be submitted at the start of the evaluation procedure. In the case of a rolling review, CHMP Rapporteurs are appointed whilst development is still ongoing and the Agency reviews data as they become available.

Several rolling review cycles can be carried out during the evaluation of one product as data continue to emerge, with each cycle lasting around two weeks depending on the amount of data to be assessed. Once the data package is complete, the developer submits a formal marketing authorisation application which is then processed under a shortened timetable.

While the overall review timeline for remdesivir cannot be anticipated at this moment, it is expected that this procedure will allow EMA to complete its assessment significantly earlier compared with a regular evaluation procedure, while still ensuring a robust scientific opinion is reached.

The CHMP’s decision to start the rolling review of remdesivir is based on preliminary results from the ACTT study, which suggest a beneficial effect of remdesivir in the treatment of hospitalised patients with mild-to-moderate or severe COVID-19. However, EMA has not yet evaluated the full study and it is too early to draw any conclusions regarding the benefit-risk balance of the medicine.

Any new data that becomes available for evaluation during this rolling review need to be considered in the context of all other existing data. The CHMP will evaluate all data on remdesivir, including evidence from a recently published study from China and other clinical trials and conclude on the medicine’s benefits and risks as soon as possible.

Although remdesivir is not yet authorised in the European Union, it is available to patients through clinical trials and so-called ‘compassionate use’ programmes through which patients can get access to unauthorised medicines in emergency situations.

More about the medicine

Remdesivir is an antiviral medicine which is being investigated for the treatment of COVID-19. Remdesivir is a ‘viral RNA polymerase inhibitor’ (a medicine that interferes with the production of viral genetic material, preventing the virus from multiplying). It has shown broad in vitro activity against different RNA viruses, including SARS-CoV-2 and was originally developed for the treatment of Ebola virus disease.

Remdesivir is being developed by Gilead Sciences Ireland CU and is given by infusion (drip) into a vein.

Information on compassionate use for remdesivir in the EU is available.

Top Stories

Anastasiades unveils new package to boost economy

  President Nicos Anastasiades on Wednesday announced a new package of 10 measures to help the economy through the coronavirus crisis that includes liquidity, guarantees...

NPLs in the Cyprus banking system decline below €9 billion

Non-performing loans (NPLs) in the Cypriot banking system declined to €8.97 billion in the end of 2019, with the NPL rate amounting to 27.9%...

Prodromou says no intention to discriminate against disabled pupils, asks parents to work with experts on solutions

Education Minister Prodromos Prodromou addressed anew on Wednesday the backlash that followed an announcement on May 20 that children with disabilities were not to...

No new Covid-19 cases on Wednesday

  There were no new Covid-19 cases in Cyprus on Wednesday the Health Ministry said, only the second time of zero cases since the start...

Paphos most booked holiday destination for Britons in April, May 2021

  Paphos is the most booked destination for British holidaymakers in April and May next year, the Daily Mail reported on Wednesday citing data collected...

Taste

Traditional salads that will blow your mind away

This traditional salads will make you actually love salads! Cyprus may be famous for souvla and kleftiko but if you try the traditional salads with...

Honey Balls

As you stroll down Onasagorou street in the old city of Nicosia and suddenly feel the need for something sweet, follow the smell of...

Octopus with Oregano

Ingredients: (Serves 4) 1 kg octopus ½ tsp dry oregano Pepper 3 tbsp olive oil 2 tbsp vinegar or lemon juice Preparation: Clean the octopus thoroughly under cold running water. Place the octopus...

Fish meatballs

In a bowl, mix the finely chopped onion and parsley. Boil the fish, cut into small pieces and add to the bowl. Add salt...